Increasing surgical volumes to boost use of tissue sealants and topical haemostats, says Frost & Sullivan

13-Feb-2013 - United Kingdom

The need for quality care, especially for a rapidly ageing population, is a strong driving factor for the tissue sealants and haemostats market in Western Europe. Technologically advanced products that enhance surgical efficiency and patient safety will also boost market prospects.

New analysis from Frost & Sullivan, Western European Tissue Sealants and Topical Hemostats Market, finds that the market earned revenues of $438.1 million in 2011 and estimates this to reach $685.5 million in 2016. The research covers tissue sealants (fibrin and synthetic) and topical haemostats (gelatine-based, collagen-based, thrombin-based, oxidized-regenerated cellulose-based and combination).

“The demand for tissue sealants and topical haemostats products is directly proportional to the total number of surgical procedures performed,” notes Frost & Sullivan Research Analyst Brahadeesh Chandrasekaran. “As Europe’s population ages, the volume and range of surgical procedures conducted is set to increase. This will promote demand for tissue sealants and topical haemostats, because both peri-operative and post-operative bleeding requires immediate attention during complex surgeries.”

Product innovation – such as sealants with drug-delivery applications or novel applicator systems that improve ease-of-use for surgeons – will further encourage the uptake of tissue sealants and topical haemostats. Another positive trend is the development of recombinant- and plant-based and combinatory products. Such products are set to address patient safety concerns that are currently impeding market growth.

At present, most sealants and haemostats are used with high benefits and no complications. In some cases, however, there have been concerns related to biocompatibility and infection-associated risks. This is because some products contain animal-derived components, while others derived from human plasma are subject to the risk of transmission of viral diseases inherent in plasma-derived products.

“This has triggered significant growth in plant-based and combinatory products, because they have proven to be safe for patients,” remarks Chandrasekaran. “Manufacturers that already have green or plant-based products have an edge, provided their products are backed by strong clinical evidence.”

https://www.bionity.com/en/news/141636/increasing-surgical-volumes-to-boost-use-of-tissue-sealants-and-topical-haemostats-says-frost-sullivan.html